Meeting
2018 ASCO Annual Meeting
Etoposide and cisplatin (EP) for metastatic good-risk germ cell tumors (GCTs): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 944 patients (pts).
Authors
Samuel Funt
Memorial Sloan Kettering Cancer Center, New York, NY
Samuel Funt , Deaglan Joseph McHugh , Stephanie Tsai , Devon O'Donnell , Andrea Knezevic , Sujata Patil , Deborah Silber , Victor E. Reuter , Joel Sheinfeld , Brett Stewart Carver , Maryann Carousso , Robert J. Motzer , Dean F. Bajorin , George J. Bosl , Darren R. Feldman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Germ Cell/Testicular
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4550)
DOI
10.1200/JCO.2018.36.15_suppl.4550
Abstract #
4550
Poster Bd #
376
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT).
First Author: Deaglan Joseph McHugh
Poster
2018 ASCO Annual Meeting
Retroperitoneal cancer viability after postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in good risk germ cell tumors (GCTs).
First Author: Fadi Taza
Poster
2018 Genitourinary Cancers Symposium
Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT).
First Author: Deaglan Joseph McHugh
First Author: Suliman Boulos